0639 GMT - Fresenius Medical Care's results should see a positive share-price response on a higher net profit and sales and earnings that topped views, Morgan Stanley analysts say in a note. The German dialysis company's sales and earnings beat was driven by higher demand for is care enablement segment and cost discipline, they say. The company's reiterated full-year outlook for revenue and operating profit and a stable U.S. market treatment growth is a positive, they add. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
May 06, 2025 02:42 ET (06:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。